Gsk (GSK) Long-Term Investments (2009 - 2026)

Gsk (GSK) has 10 years of Long-Term Investments data on file, last reported at $123.2 million in Q4 2024.

• In Q4 2024, Long-Term Investments rose 80.5% year-over-year to $123.2 million; the TTM figure through Dec 2024 stood at $123.2 million (up 80.5% YoY), while the FY2024 annual figure was $123.2 million, up 80.5% from the prior year.
• Long-Term Investments climbed to $123.2 million in Q4 2024, from $68.3 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $1.7 billion in Q4 2022 and bottomed at $6.6 million in Q4 2020.
• A 5-year average of $388.6 million and a median of $68.3 million in 2023 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2020 — Long-Term Investments plunged 98.36% — and 2022, when it soared 6991.46%.
• Year by year, Long-Term Investments stood at $6.6 million in 2020, then jumped by 267.51% to $24.3 million in 2021, then soared by 6991.46% to $1.7 billion in 2022, then plunged by 96.03% to $68.3 million in 2023, then jumped by 80.5% to $123.2 million in 2024.
• The last three Long-Term Investments figures came in at $123.2 million (Q4 2024), $68.3 million (Q4 2023), and $1.7 billion (Q4 2022), per Business Quant data.

Peer Comparison